Ufovax successfully extended its Nanoparticle vaccine technology to SARS-CoV-2

Ufovax, a spin-off vaccine company from Scripps Research, announced today that the company has successfully extended its patented one component self-assembling protein nanoparticle (1c-SA p NP) vaccine platform technology to a vaccine against the coronavirus SARS-CoV-2. The vaccine prototype features SARS-CoV-2 protein spikes protruding from a protein nanoparticle scaffold. […]

Click here to view original web page at www.oleantimesherald.com

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.